Commerzbank Aktiengesellschaft FI Has $16.15 Million Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Commerzbank Aktiengesellschaft FI lifted its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 151.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 132,698 shares of the biopharmaceutical company’s stock after buying an additional 79,943 shares during the period. Commerzbank Aktiengesellschaft FI owned about 0.06% of Alexion Pharmaceuticals worth $16,145,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ALXN. Morgan Stanley lifted its position in shares of Alexion Pharmaceuticals by 112.0% in the 1st quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock worth $70,983,000 after purchasing an additional 309,299 shares during the period. DekaBank Deutsche Girozentrale lifted its position in shares of Alexion Pharmaceuticals by 18.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 114,493 shares of the biopharmaceutical company’s stock worth $14,017,000 after purchasing an additional 17,642 shares during the period. Sumitomo Mitsui Asset Management Company LTD lifted its position in shares of Alexion Pharmaceuticals by 10.9% in the 1st quarter. Sumitomo Mitsui Asset Management Company LTD now owns 18,859 shares of the biopharmaceutical company’s stock worth $2,286,000 after purchasing an additional 1,849 shares during the period. Baird Financial Group Inc. lifted its position in shares of Alexion Pharmaceuticals by 219.0% in the 1st quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $1,771,000 after purchasing an additional 10,028 shares during the period. Finally, LS Investment Advisors LLC lifted its position in shares of Alexion Pharmaceuticals by 13.0% in the 1st quarter. LS Investment Advisors LLC now owns 6,131 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 706 shares during the period. Hedge funds and other institutional investors own 94.26% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://ledgergazette.com/2017/09/17/commerzbank-aktiengesellschaft-fi-acquires-79943-shares-of-alexion-pharmaceuticals-inc-alxn.html.

In related news, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Julie O’neill sold 4,375 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total value of $636,300.00. Following the completion of the transaction, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. Insiders sold 17,070 shares of company stock worth $2,416,869 over the last quarter. 4.35% of the stock is currently owned by company insiders.

ALXN has been the subject of several research reports. J P Morgan Chase & Co cut shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Tuesday, May 23rd. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Barclays PLC reissued an “overweight” rating and set a $155.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $157.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Five analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $157.13.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 146.69 on Friday. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The firm has a market cap of $32.74 billion, a PE ratio of 63.61 and a beta of 1.40. The company has a 50 day moving average of $138.83 and a 200-day moving average of $124.75.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. The company had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period last year, the business posted $1.13 earnings per share. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.62 earnings per share for the current year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply